Tapentadol controlled-release

Drug Profile

Tapentadol controlled-release

Alternative Names: BN200 ER; BN200 PR; CG 5503 ER; CG 5503 PR; JNS024ER; Nucynta ER; Palexia Depot; Palexia Retard; Palexia RP; Palexia SR; Palexia XR; R331333 PR; Tapenta; Tapentadol CR tamper-resistant formulation; Tapentadol CR TRF; Tapentadol ER PR2; Tapentadol ER prolonged-release 2; Tapentadol ER tamper-resistant formulation; Tapentadol ER TRF; Tapentadol extended release; Tapentadol PR; Tapentadol prolonged release; Tapentadol prolonged release granules; Yantil Retard

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Grunenthal
  • Developer Grunenthal; Janssen Pharmaceutical KK; Janssen Research & Development
  • Class Opioid analgesics; Phenols; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Alpha 2 adrenergic receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain; Diabetic neuropathies; Pain
  • Discontinued Neuropathic pain

Most Recent Events

  • 19 Jun 2015 Grunenthal terminates a phase III trial in Cancer pain in Austria, Bulgaria, Croatia, Czech Republic, France, Hungary, Moldova, Poland, Romania, Russia, Serbia and Spain (NCT01264887)
  • 11 Jun 2015 Discontinued - Phase-II for Neuropathic pain in Japan (PO)
  • 11 Jun 2015 Launched for Pain in Estonia, Croatia, Bulgaria, Malta, Romania, Slovakia, Slovenia and Serbia (PO) before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top